Moderna has reported a decline in its revenue for the fourth quarter of 2024, according to a recent publication by Yahoo Finance. The report highlights a shift in the company’s financial performance during this period.

Shares of Moderna tumbled sharply on Monday after the vaccine maker projected a larger-than-anticipated drop in sales for 2025. The unexpected forecast surprised analysts and investors, signaling potential challenges ahead for the biotech firm.